Patient-Centred Innovations for Persons With Multimorbidity - Ontario

Key facts

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Principal Investigator

Moira Stewart

Western University

Intervention

TIP / IMPACT Plus Care Coordination(behavioral)

Enrollment

175 enrolled

Eligibility

18-80 years · All sexes

Timeline

2016 – 2022

Study locations (9)

• Western University, London, Ontario, Canada
• Mount Sinai Hospital, Toronto, Ontario, Canada
• Providence Healthcare, Toronto, Ontario, Canada
• St. Michael's Hospital, Toronto, Ontario, Canada
• Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
• Toronto Central Community Care Access Centre, Toronto, Ontario, Canada
• Toronto East General Hospital, Toronto, Ontario, Canada
• University Hospital Network, Toronto, Ontario, Canada
• Women's College Hospital, Toronto, Ontario, Canada

Collaborators

Western University, Canada · Université de Sherbrooke · Canadian Institutes of Health Research (CIHR) · Sunnybrook Health Sciences Centre · Unity Health Toronto · University Health Network, Toronto · Michael Garron Hospital · Providence Healthcare · Mount Sinai Hospital, Canada · Toronto Central Community Care Access Centre · Women's College Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06882486
  Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
  Institut Paoli-Calmettes
• RECRUITINGPHASE1NCT07517198
  Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
• RECRUITINGNANCT06907095
  Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
  Gustave Roussy, Cancer Campus, Grand Paris
• RECRUITINGNANCT07461090
  Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis
  Menoufia University
• RECRUITINGPHASE1NCT07195682
  A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT07006688
  A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
  Servier Bio-Innovation LLC
• RECRUITINGPHASE1, PHASE2NCT07219576
  Retifanlimab and Ruxolitinib In Solid Malignancies
  University of California, San Diego
• RECRUITINGPHASE1, PHASE2NCT07239596
  Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
  Suzhou Suncadia Biopharmaceuticals Co., Ltd.

See all trials for Acquired cystic disease-associated renal cell carcinoma →